About Novartis
Novartis news and updates
Nativa files suit against Novartis AG
After losing its initial legal bid, Nativa filed a lawsuit against Novartis and Rospatent to grant a compulsory license for a patent to a foreign company.
Jan 1, 2022 | epam.ruCambrian Biopharma partnered with Novartis AG on Feb 16th 22'.
Following the efforts of Adicet Bio, formerly resTORbio, to create therapies based on the mTOR pathway, Cambrian Biopharma is working with Novartis to use this pathway in order to increase healthspan and lifespan.
Jan 1, 2022 | lifespan.ioNovartis AG launched STEP Program TM on Jan 1st 17'.
Novartis launched the STEP Program TM in 2017 to fund projects from US-based 501(c)(3) nonprofit patient advocacy organizations that help to address gaps in care or unmet patient needs.
Jan 1, 2021 | novartis.usNovartis Pharmaceuticals Corporation sells assets to Sterling Pharma Solutions
Novartis has sold its manufacturing plant in Ringaskiddy in Cork to global contract development and manufacturing business Sterling Pharma Solutions.
Jan 1, 2022 | rte.ieCharles Davis leaves Novartis Pharmaceuticals Corporation as vice president, PK sciences
Charles Davis, Ph.D., comes to Tango from the Novartis Institutes for BioMedical Research, where he served as vice president, PK sciences.
Jan 1, 2018 | tangotx.comNovartis Pharmaceuticals Corporation partners with Sage Bionetworks
Novartis is partnering on what it has dubbed the elevateMS study with Sage Bionetworks.
Jan 1, 2017 | multiplesclerosisnewstoday.comAduro partnered with Novartis Pharmaceuticals Corporation on Jan 1st 15'.
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced the presentation of data from an ongoing Phase 1b clinical trial in collaboration with Novartis.
Jan 1, 2019 | globenewswire.comNovartis Pharmaceuticals Corporation partners with Novartis Oncology
During the option period, Novartis and BeiGene will collaborate on the clinical development of ociperlimab in combination with tislelizumab, with Novartis designing, sponsoring, conducting, and funding global combination clinical trials.
Jan 1, 2021 | purepharmanews.comMatly leaves Novartis Pharmaceuticals Corporation as Vice President
Mr. Matly joins us from Novartis where he served as the global Vice President of the MDS/AML franchise, one of the largest potential growth areas of Novartis Oncology, leading the launch preparation of their flagship program, as well as ensuring commercial success of the entire AML/MDS portfolio.
Jan 1, 2021 | kpvi.comDimitris left Novartis Pharmaceuticals Corporation on Nov 6th 17'.
Dimitris joins Tango from Novartis Oncology, where he worked most recently in oncology business development and licensing roles.
Jan 1, 2017 | tangotx.comLiveTiles Limited partners with Novartis Pharmaceuticals Corporation
LiveTiles and Microsoft have partnered to develop a new corporate intranet with pharmaceutical giant Novartis becoming their first joint customer.
Jan 1, 2019 | arnnet.com.auNovartis Pharmaceuticals Corporation launches AAV gene therapy programme
Novartis has announced its acquisition of Arctos Medical as it looks to expand its gene therapy pipeline further, adding a pre-clinical optogenetics-based AAV gene therapy programme to its portfolio.
Jan 1, 2021 | pharmatimes.comNovartis Pharmaceuticals Corporation launched electronic patient access program for advanced breast cancer on Feb 16th 21'.
In observance of Breast Cancer Awareness Month in October last year, Novartis and Docquity launched an electronic patient access program for advanced breast cancer.
Jan 1, 2022 | businessmirror.com.phNovartis Pharmaceuticals Corporation is developing disease-modifying treatments for Parkinson’s Disease
UCB and Novartis partner to develop disease-modifying treatments for Parkinson’s Disease.
Jan 1, 2021 | pharmaceutical-technology.comNovartis Pharmaceuticals Corporation partners with Ubisoft ®
Novartis said it will work in collaboration with video game creator Ubisoft and McGill University to develop the purchased digital technology for the treatment of the lazy eye condition, also known as amblyopia.
Jan 1, 2020 | yahoo.comLeprosy partnered with Novartis Pharmaceuticals Corporation on Jan 1st 20'.
This year, American Leprosy Missions partnered with Novartis to offer two $20,000 awards to a finalist in the data and analytics domain and a finalist with a diagnostics proposal.
Jan 1, 2020 | ntdinnovation.orgTyagarajan left Novartis Pharmaceuticals Corporation as Executive Director and Global Head, Late Stage CMC Strategy for CGT on Feb 2nd 22'.
Dr. Tyagarajan joins the company from Novartis, where she was most recently Executive Director and Global Head, Late Stage CMC Strategy for CGT.
Jan 1, 2022 | yahoo.comNovartis Pharmaceuticals Corporation launches two key technology-based platforms ‘Choice
With the advent of remote working, Novartis launched two key technology-based platforms ‘Choice with Responsibility’ and ‘Energised for Life’ to help associates navigate the radical shift in ways of working and boost their mental well-being.
Jan 1, 2022 | galencentre.orgNovartis Pharmaceuticals Corporation is developing therapeutic applications of Fibroblast Activation Protein targeting agents including FAPI-46 and FAPI-74 on Mar 1st 21'.
In March 2021, Novartis announced the commercialization and obtained the rights to develop the therapeutic applications of Fibroblast Activation Protein (FAP) targeting agents including FAPI-46 and FAPI-74, through an assignment agreement with iTheranostics, Inc., an affiliate of SOFIE Biosciences, Inc.
Jan 1, 2022 | biospace.comNovartis Pharmaceuticals Corporation is developing adenovirus viral vectors
Novartis and Voyager Therapeutics have joined forces to develop adenovirus viral vectors (AAV) that could cross the blood-brain barrier, potentially delivering gene therapy deep into the brain.
Jan 1, 2022 | fdanews.comGenveon partners with Novartis Pharmaceuticals Corporation
Genveon has also entered into an agreement with Novartis to produce all of its products for a period of 4+2 years.
Jan 1, 2021 | genveon.comNovartis Pharmaceuticals Corporation launches Kymriah
Novartis announced Kymriah ® (tisagenlecleucel) demonstrated strong efficacy in high-risk patients with relapsed or refractory (r/r) follicular lymphoma (FL) based on a subgroup analysis from an approximately 17-month median follow-up of the pivotal Phase II ELARA study 1.
Jan 1, 2021 | prnewswire.comNovartis Pharmaceuticals Corporation partnered with Carisma Therapeutics, Inc. on Mar 10th 22'.
Initial agreement covers reservation of state-of-the-art cell and gene facility in Morris Plains, U.S. Basel, March 10, 2022 — Novartis has signed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to manufacture the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors.
Jan 1, 2022 | novartis.comNovartis Pharmaceuticals Corporation is developing nervous system disorder treatments
With Voyager's drug delivery technology, Novartis seeks to overcome the delivery and distribution problems of AAV (adeno-associated virus)-based gene therapies and develop nervous system disorder treatments.
Jan 1, 2022 | 3billion.ioNovartis Pharmaceuticals Corporation hired Natalia as head on Sep 1st 19'.
Natalia was appointed as head of the Novartis Group in September 2019, also retaining her position as General Manager of the company's oncology business in Russia, Ukraine and the CIS since 2014.
Jan 1, 2022 | aipm.orgNovartis Pharmaceuticals Corporation launched FocalView app on Apr 1st 18'.
For Instance, In April 2018, Novartis launched its FocalView app, a first-of-its-kind app designed to modernize ophthalmic clinical trials.
Jan 1, 2022 | benzinga.comFernandez de Castro leaves Novartis Pharmaceuticals Corporation as general counsel
Fernandez de Castro, who is not a lawyer, came from Novartis, where she was a strategic assistant to the general counsel.
Jan 1, 2022 | bloomberglaw.comNovartis Pharmaceuticals Corporation hires Kuhn as CEO and chairman
Dr. Kuhn joins Daniel Vasella, M.D., former CEO and chairman of Novartis, and the company's cofounders as board members.
Jan 1, 2022 | yahoo.comNovartis Pharmaceuticals Corporation is developing COVID-19 vaccine
ATS’s corporate sponsors also include vaccine giant Merck, CSL Behring, which partnered AstraZeneca to produce its COVID-19 vaccine, and Novartis, which like Sanofi partnered with Pfizer to produce its COVID-19 vaccine.
Jan 1, 2022 | thekapnobatai.comNovartis Pharmaceuticals Corporation invests into Intellia Therapeutics, Inc. in $15M
At that time, Intellia received US$15 million in series A funding, led by Atlas and Switzerland-based global healthcare giant Novartis.
Jan 1, 2016 | patentology.com.auOursisterhood partners with Novartis Pharmaceuticals Corporation
As for the Southern African and Africa expansion, Sisterhood SA is partnering with the New Africa Education Foundation, Novartis Pharmaceuticals, the Africa Trade Council and the East African Health Platform.
Jan 1, 2022 | svai.africaNovartis Pharmaceuticals Corporation expands facilities to New Jersey, United States
With the Carisma agreement, Novartis is turning that expertise outwards, agreeing to produce the biotech's experimental drug at its cell therapy site in Morris Plains, New Jersey.
Jan 1, 2022 | biopharmadive.comNovartis Pharmaceuticals Corporation launches Aimovig Ally program and Aimovig Copay Program
While out-of-pocket costs will vary based on patient insurance status, Amgen and Novartis have launched the Aimovig Ally program and Aimovig Copay Program to help reduce costs to as low as $5 per month for commercially-insured patients and help uninsured patients identify potential access resources.
Jan 1, 2018 | neurologyadvisor.comNovartis Pharmaceuticals Corporation is developing contacts that could help patients monitor insulin levels on Jan 1st 14'.
In 2014, the company teamed up with Novartis to develop contacts that could help patients monitor insulin levels.
Jan 1, 2018 | mddionline.comNovartis Pharmaceuticals Corporation hires Marie-France Tschudin as president of innovative medicines in the U.S.
Novartis appointed Marie-France Tschudin as president of innovative medicines international and chief commercial officer and Victor Bulto as president of innovative medicines in the U.S. Steffen Lang will take over as president of operations, while Shreeram Aradhye will become president of global drug development and chief medical officer.
Jan 1, 2022 | benzinga.comBanard leaves Novartis Pharmaceuticals Corporation as Global Head, Technical Operations
Ms. Banard comes to Atara from Novartis, where, as Global Head, Technical Operations, Cell & Gene Therapy (C>) Platform, she led C> lifecycle management strategy and execution and established the Technical Operations strategy for the company’s cell therapy oncology pipeline.
Jan 1, 2022 | bakersfield.comNovartis Pharmaceuticals Corporation is developing canakinumab and spartalizumab
Through Precision Promise, Novartis will be testing canakinumab (IL-1 beta inhibitor) and spartalizumab (PD-1 inhibitor) in combination with nab-paclitaxel and gemcitabine.
Jan 1, 2022 | appliedradiationoncology.comNovartis Pharmaceuticals Corporation launches 40 new studies of Entresto in a clinical program it calls FortiHFy
Novartis also launched 40 new studies of Entresto in a clinical program it calls FortiHFy.
Jan 1, 2017 | fiercepharma.comNovartis Pharmaceuticals Corporation launches Paradigm-HF
Novartis announced a new post-hoc analysis of the phase 3 heart failure study, Paradigm-HF, which demonstrated treatment with Entresto helped to preserve kidney function, as assessed by estimated glomerular filtration rate, in patients with heart failure with reduced ejection fraction.
Jan 1, 2018 | healio.comNovartis Pharmaceuticals Corporation is developing CTL019
Novartis is teaming up with a gene therapy developer to produce lentiviral vectors for its highly anticipated drug CTL019 (tisagenlecleucel) as well as other CAR-T candidates.
Jan 1, 2017 | biopharmadive.comNovartis Pharmaceuticals Corporation sold assets to CSL Limited in the amount of $275M on Jan 1st 15'.
Seqirus has been making seasonal flu jabs since 2015 after parent company CSL Limited acquired Novartis’ global influenza vaccine business.
Jan 1, 2018 | bioprocessintl.comNovartis Pharmaceuticals Corporation sells assets to CSL Limited
Seqirus was established in 2015 when parent company, CSL Limited, acquired the influenza vaccine business of Novartis.
Jan 1, 2017 | seqirus.usNovartis Pharmaceuticals Corporation partnered with Sandoz on Dec 25th 18'.
Under the new agreement Tilray and Novartis announced Tuesday, Tilray Canada will collaborate with Sandoz AG.
Jan 1, 2017 | hightimes.comNovartis Pharmaceuticals Corporation launched Kisqali on Dec 8th 21'.
Novartis today announced new Kisqali ® (ribociclib) data demonstrating a consistent overall survival (OS) benefit with Kisqali plus endocrine therapy (ET) across genomic subtypes of hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer (mBC), similarly in the indolent as well as in the aggressive, endocrine therapy (ET)-resistant subtypes 6.
Jan 1, 2021 | novartis.usWerner leaves Novartis Pharmaceuticals Corporation as worldwide franchise head for solid tumors
Werner comes from Novartis, where she was worldwide franchise head for solid tumors.
Jan 1, 2022 | fiercepharma.comNovartis Pharmaceuticals Corporation is developing JDQ443
Novartis is testing JDQ443, an investigational Kras G12C inhibitor, in a phase 1/2 trial in patients with Kras G12C mutated advanced solid cancer.
Jan 1, 2021 | koreabiomed.comNovartis Pharmaceuticals Corporation receives award Best in Measurement, Post-Campaign Analysis
Оur work with Novartis on reshaping quarterly financial results comms strategy based on data won the Best in Measurement, Post-Campaign Analysis award.
Jan 1, 2022 | commetric.comNovartis Pharmaceuticals Corporation hired Ronny Gal as chief strategy and growth officer on May 3rd 22'.
Novartis on Tuesday named Ronny Gal, a longtime analyst with advisory firm Bernstein, as its chief strategy and growth officer, the latest move in an organizational shakeup the Swiss drug company announced in early April.
Jan 1, 2022 | biopharmadive.comNovartis Pharmaceuticals Corporation launched malaria treatment on Jan 1st 99'.
In 1999, Novartis, in partnership with Medicines for Malaria Venture, introduced its first malaria treatment, a highly effective fixed-dose artemisinin-based combination therapy.
Jan 1, 2022 | graphic.com.ghNovartis Pharmaceuticals Corporation launches updated median overall survival results for Kisqali
With further follow-up of MONALEESA-3, Kisqali plus fulvestrant achieved a median overall survival (OS) of more than five-and-a-half years (67.6 months) in the first-line (1L) setting for postmenopausal women living with HR+/HER2- aBC 1 Basel, May 4, 2022 — Novartis today announced updated median overall survival (OS) results for Kisqali ® (ribociclib) in combination with fulvestrant in the first-line subgroup of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
Jan 1, 2022 | globenewswire.comAmeet Mallik left Novartis Pharmaceuticals Corporation as CEO on May 1st 21'.
Ameet Mallik left Novartis to claim the CEO spot at Rafael Holdings back in May, taking the reins from founder Howard Jonas.
Jan 1, 2021 | endpts.comNovartis Pharmaceuticals Corporation will launch blockbuster idiopathic pulmonary fibrosis therapy Esbriet on May 19th 22'.
Sandoz has launched the first fully substitutable U.S. generic of Roche’s blockbuster idiopathic pulmonary fibrosis (IPF) therapy Esbriet, the Novartis unit said Thursday.
Jan 1, 2022 | fiercepharma.comNovartis Pharmaceuticals Corporation launched clinical data for JDQ443 on Apr 11th 22'.
Novartis today announced promising clinical data for JDQ443, an investigational selective, covalent, and orally bioavailable KRASG12C inhibitor at the annual meeting of American Association for Cancer Research (AACR).
Jan 1, 2022 | medical-leaders-thailand.comNovartis Pharmaceuticals Corporation has issues with bribery scandal in which the company allegedly paid public officials
T he Greek health ministry plans to seek compensation from Novartis over a long-running bribery scandal in which the company allegedly paid public officials and health care providers to boost prescriptions for its medicines and maintain inflated prices.
Jan 1, 2022 | statnews.comBilotta retired from Novartis Pharmaceuticals Corporation on Jan 1st 13'.
Bilotta retired from Novartis in 2013 and said that now, “he wants to work to change health care practices and laws that harm patients and taxpayers.”
Jan 1, 2020 | whistleblowersblog.orgLynne retires from Novartis Pharmaceuticals Corporation
Lynne retired from Novartis where she worked for many years as the Research Librarian.
Jan 1, 2022 | outerbanksvoice.comNovartis Pharmaceuticals Corporation has issues with severe financial crisis
The alleged bribery allowed Novartis to increase prescription sales at inflated prices EU-wide, and gain a more dominant position in the Greek healthcare market, despite the fact that Greece was facing a severe financial crisis at the time.
Jan 1, 2021 | occrp.orgNovartis Pharmaceuticals Corporation hired Zia on Jan 1st 87'.
Zia had joined Novartis in 1987 and held responsibilities across market research, brand management, marketing, and other functions in Ireland, Singapore, Saudi Arabia, Canada, Switzerland, Turkey and India.
Jan 1, 2022 | thehindubusinessline.comNovartis Pharmaceuticals Corporation launches Phase 3b SMART trial
With this in mind, Novartis Gene Therapies launched the global Phase 3b SMART trial ( NCT04851873 ) to test Zolgensma in up to 24 children with SMA symptoms and weighing 8.5 to 21 kg (about 18 to 46 lbs).
Jan 1, 2022 | smanewstoday.comRoche identified as competitor of Novartis Pharmaceuticals Corporation on Jan 1st 19'.
Twin late-stage trials of Roche’s ophthalmology drug faricimab have hit the mark in “wet” age-related macular degeneration trial, as the company’s challenge to rivals from Novartis and Bayer strengthens.
Jan 1, 2019 | pharmaphorum.comNovartis Pharmaceuticals Corporation sold assets to Gud Knight on May 26th 21'.
On May 26, 2021, Knight completed the acquisition of the exclusive rights to manufacture, market and sell Exelon ® in Canada and Latin America as well as the exclusive license to use the intellectual property and the Exelon trademark, from Novartis within those territories.
Jan 1, 2022 | digitaljournal.comNovartis Pharmaceuticals Corporation partners with Hematology
Novartis, a leading global medicines company, has announced a partnership with the American Society of Hematology (ASH) to provide six more African nations with the technology to track and better manage sickle cell disease (SCD).
Jan 1, 2022 | businessghana.comNovartis Pharmaceuticals Corporation is developing NIZ985
The pharmaceutical company Novartis has been developing a "superagonist" agent, NIZ985, which is designed to enhance IL-15/IL-15Rα pathway signals with reduced potential for harmful inflammatory effects.
Jan 1, 2022 | news-medical.netNovartis Pharmaceuticals Corporation is developing 12-month extensive training programme for Emirati graduates holding pharmacy degrees
ABU DHABI, The Ministry of Health and Prevention (MoHAP) has signed a Memorandum of Understanding (MoU) with Novartis, a global healthcare company based in Switzerland, to develop a 12-month extensive training programme for Emirati graduates holding pharmacy degrees.
Jan 1, 2022 | emiratespressreleases.comNovartis Pharmaceuticals Corporation has issues with potential securities laws violations
An investigation for investors in Novartis AG (NYSE: NVS) shares over potential securities laws violations by Novartis AG.
Jan 1, 2022 | openpr.comNovartis Pharmaceuticals Corporation launches Tafinlar + Mekinist
Novartis today announced Tafinlar ® (dabrafenib) + Mekinist ® (trametinib) significantly improved efficacy in patients ages 1 to 17 years old with BRAF V600 pediatric low-grade glioma (pLGG) requiring first systemic treatment compared to chemotherapy, the current standard-of-care for these patients 1.
Jan 1, 2022 | itbusinessnet.comNovartis Pharmaceuticals Corporation receives award The Diamond SABRE Award for Superior Achievement in Research and Planning at 2022 SABRE Awards EMEA
Commetric Ltd. is honoured to announce that its work with Novartis won The Diamond SABRE Award for Superior Achievement in Research and Planning at the 2022 SABRE Awards EMEA.
Jan 1, 2022 | commetric.comNovartis Pharmaceuticals Corporation is developing saRNA vaccine on Jun 9th 21'.
And last year, a Yale researcher partnered with pharmaceutical company Novartis to develop a saRNA vaccine to protect against the malaria parasite.
Jan 1, 2022 | labiotech.euNovartis Pharmaceuticals Corporation has issues with securities fraud or other unlawful business practices
The investigation concerns whether Novartis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Jan 1, 2022 | prnewswire.comNovartis Pharmaceuticals Corporation partners with Alphabet International GmbH
Novartis has partnered with Verily Life Sciences, and Alphabet company, on sensors to be embedded in contact lenses.
Jan 1, 2018 | forbes.comNovartis Pharmaceuticals Corporation had issues with illegal practices on May 20th 22'.
The government is “taking all measures to hold Novartis accountable and compensate the Greek state for its illegal practices,” the health department said in a statement Friday.
Jan 1, 2022 | fiercepharma.comNovartis Pharmaceuticals Corporation files suit against Eli Lilly & Co.
After acquiring a patent portfolio related to the psoriasis drug Taltz, Novartis AG sued Eli Lilly for patent infringement in several European courts.
Jan 1, 2022 | jdsupra.comNovartis Pharmaceuticals Corporation partners with Aural Analytics, Inc.
(Kubkoo/iStock/Getty Images Plus) Novartis and Merck-backed Koneksa Health has partnered with speech collection and analysis tech firm Aural Analytics to expand its “digital biomarker” offering.
Jan 1, 2022 | fiercebiotech.comNovartis Pharmaceuticals Corporation will partner with Precision Biosciences, Inc on Jun 28th 22'.
Still, Novartis is exploring other approaches, recently joining forces with the Bill and Melinda Gates Foundation and, on Tuesday, partnering with Precision.
Jan 1, 2022 | biopharmadive.comNovartis Pharmaceuticals Corporation is developing potentially curative treatments for disorders including sickle cell disease and beta thalassaemia
Novartis and Precision BioSciences (Precision) have announced an in vivo gene editing research and development collaboration to develop potentially curative treatments for disorders including sickle cell disease (SCD) and beta thalassaemia.
Jan 1, 2022 | pmlive.comNovartis Pharmaceuticals Corporation is developing anti-parasitic therapies for Chagas disease
The company said the Novartis Institute for Tropical Diseases (NITD) in collaboration with Wellcome is working to discover new anti-parasitic therapies for Chagas disease.
Jan 1, 2022 | seekingalpha.comNovartis Pharmaceuticals Corporation had issues with patent lawsuit related to its blockbuster multiple sclerosis drug on Mar 8th 22'.
A U.S. appeals court ruled against Novartis ( NYSE: NVS ) ( OTCPK:NVSEF ), dealing a blow to the Swiss drugmaker’s claims in a patent lawsuit related to its blockbuster multiple sclerosis drug, Gilenya.
Jan 1, 2022 | seekingalpha.comNovartis Pharmaceuticals Corporation decreases headcount by 8000
[Novartis] Novartis today disclosed plans to eliminate about 8,000 jobs worldwide as part of a cost-cutting effort intended to save the pharma giant at least $1 billion by 2024—part of a restructuring whose outlines were announced in April.
Jan 1, 2022 | genengnews.comNovartis Pharmaceuticals Corporation partners with DigitasLbi
Novartis has launched its first digital campaign with DigitasLBi, with a focus on raising awareness of heart failure.
Jan 1, 2017 | marketing-interactive.comNovartis Pharmaceuticals Corporation hires Agrawal
Agrawal joins from pharmaceutical firm Novartis, where he helped shape the corporate strategy and led a number of global transformation efforts.
Jan 1, 2022 | accountancytoday.co.ukNovartis Pharmaceuticals Corporation launched ITP Pocket Log on Jan 1st 20'.
• In January 2020, Novartis in association with The ITP Support Association announced the launch of ITP Pocket Log, designed to help people manage and track their ITP on the move, which is available on Google Play and Apple App Store.
Jan 1, 2022 | globenewswire.comNovartis Pharmaceuticals Corporation is developing AI algorithms
Latest to join the fray are Novartis and Anumana—a joint venture of the Mayo Clinic and Nference—which have teamed up to develop new AI algorithms.
Jan 1, 2022 | fiercebiotech.comNovartis Pharmaceuticals Corporation is developing artificial intelligence-based solution for cardiovascular diseases
Novartis is partnering with algorithms startup Anumana to develop a new artificial intelligence-based solution for cardiovascular diseases.
Jan 1, 2022 | medcitynews.comNovartis Pharmaceuticals Corporation hires Vasant Narasimhan as CEO
Vasant Narasimhan will become the new CEO of Swiss medical company Novartis as Joseph Jiminez retires after eight years.
Jan 1, 2022 | boardagenda.comMayo Clinic partnered with Novartis Pharmaceuticals Corporation on Jul 12th 22'.
Anumana, a joint venture between EHR data company nference and the Mayo Clinic, announced last week it had entered a strategic partnership with pharma giant Novartis to develop artificial intelligence tools to detect cardiovascular diseases.
Jan 1, 2022 | mobihealthnews.comRaj leaves Novartis Pharmaceuticals Corporation
Raj joins from pharmaceutical firm Novartis, where he has played critical roles in shaping the corporate strategy and leading a number of global transformation efforts.
Jan 1, 2022 | consultingpoint.comNovartis Pharmaceuticals Corporation is developing AI tools to detect cardiovascular diseases on Jun 20th 22'.
It recently announced a partnership with Novartis to develop AI tools to detect cardiovascular diseases.
Jan 1, 2022 | mobihealthnews.comNovartis Pharmaceuticals Corporation launches ‘Integrated Eye Health Program
The Fred Hollows Foundation and Novartis Pharmaceutical, have launched the ‘Integrated Eye Health Program’ for blindness prevention in Kenya.
Jan 1, 2022 | the254hub.comNovartis Pharmaceuticals Corporation is developing technologies for the discovery of next-generation therapeutics
Novartis and the University of California, Berkeley have extended their research-based collaboration to develop new technologies for the discovery of next-generation therapeutics, following its successes over the last five years.
Jan 1, 2022 | pharmajournalist.comJordan left Novartis Pharmaceuticals Corporation as Senior Global Program Regulatory Director on Jul 8th 22'.
Mr. Jordan joins Chimerix from Novartis where he was most recently Senior Global Program Regulatory Director.
Jan 1, 2022 | biospace.comNovartis Pharmaceuticals Corporation launches Women in Pink campaign which aims to raise awareness on Breast Cancer
Novartis, ranked among the world’s top pharmaceutical companies, has rolled out its new Women in Pink campaign which aims to raise awareness on Breast Cancer for a better quality of life for women across the Gulf region.
Jan 1, 2022 | tradearabia.comNovartis Pharmaceuticals Corporation is developing potential one-time treatment option
Most exciting this past quarter, we entered into a collaboration agreement with Novartis to develop a potential one-time treatment option for hemoglobinopathies including sickle cell disease and beta thalassemia using ARCUS for gene insertion.
Jan 1, 2022 | yahoo.comNovartis Pharmaceuticals Corporation launched Phase III CANOPY-A study evaluating adjuvant treatment with canakinumab on Aug 15th 22'.
Novartis announced today that the Phase III CANOPY-A study evaluating adjuvant treatment with canakinumab (ACZ885), an inhibitor of interleukin-1beta (IL-1β), in adult patients with stages II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) did not meet its primary endpoint of disease-free survival (DFS) versus placebo 1.
Jan 1, 2022 | novartis.comNovartis Pharmaceuticals Corporation partners with Institute for Healthcare Improvement Ihi
To enable healthcare systems to better meet patient needs, the Novartis US Foundation has partnered with the Institute for Healthcare Improvement (IHI), an independent not-for-profit organization working to advance and sustain better outcomes in health and health systems across the world.
Aug 15, 2022 | massbio.orgNovartis Pharmaceuticals Corporation launched T-Charge to CAR -T platform on Dec 1st 21'.
For instance, in December 2021, Novartis, a global healthcare company, announced the introduction of T-Charge to CAR (chimeric antigen receptor)-T platform that will serve as the foundation for various new investigational CAR-T cell therapies by Novartis.
Aug 18, 2022 | globenewswire.comNovartis Pharmaceuticals Corporation has issues with potential breaches of fiduciary duties by certain directors
An investigation was announced over potential breaches of fiduciary duties by certain directors at Novartis AG.
Aug 22, 2022 | openpr.comNovartis Pharmaceuticals Corporation partnered with NHS on Sep 1st 21'.
With NICE backing in September 2021, Novartis formed an agreement with the NHS in England to make Leqvio available to a broader patient population than in the restrictive guidelines that limited Praluent and Repatha.
Aug 19, 2022 | reconstrategy.comNovartis Pharmaceuticals Corporation closes offices in Wilson, North Carolina, United States
While Novartis originally planned to close the Wilson site in 2022, the company extended the process into late 2023 to ensure product transfers are complete.
Aug 26, 2022 | fiercepharma.comNovartis Pharmaceuticals Corporation had issues with federal lawsuit on Aug 22nd 22'.
... Novartis AG was hit with a federal lawsuit Monday alleging that Entresto, its blockbuster heart failure treatment, infringes a patent jointly held by the University of Michigan and the University of South Florida related to engineering crystals for the design of new drug compounds.
Aug 25, 2022 | bloomberglaw.comNovartis Pharmaceuticals Corporation launched community update on VIBRANT-HD on Aug 25th 22'.
This week, Novartis released a community update on VIBRANT-HD, the phase 2b study of branaplam in adults with HD.
Aug 25, 2022 | hdsa.orgNovartis Pharmaceuticals Corporation acquires Kedalion Therapeutics, Inc.
Novartis acquired Kedalion Therapeutics and its AcuStream technology, a preservative-free, electromechanical topical ocular delivery device that may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye.
Jul 7, 2022 | ophthalmologymanagement.comJay Bradner will leave Novartis Pharmaceuticals Corporation as executive on Sep 8th 22'.
Novartis appointed Merck executive Fiona Marshall as president of the Novartis Institutes for Biomedical Research to replace Jay Bradner, who is stepping down as research head at the Swiss drugmaker, it said on Thursday.
Sep 1, 2022 | kelo.comNovartis Pharmaceuticals Corporation hired Fiona Marshall as executive on Sep 1st 22'.
Novartis appointed Merck executive Fiona Marshall as president of the Novartis Institutes for Biomedical Research to replace Jay Bradner, who is stepping down as research head at the Swiss drugmaker, it said on Thursday.
Sep 1, 2022 | kelo.comNovartis Pharmaceuticals Corporation hired Jay Bradner on Jan 1st 15'.
Jay Bradner was tapped to lead the Novartis Institute for Biomedical Research in 2015.
Sep 1, 2022 | fiercebiotech.comNovartis Pharmaceuticals Corporation is developing digital patient monitoring and management for patients with melanoma
Novartis and Kaiku Health's (Kaiku) partnership to develop digital patient monitoring and management for patients with melanoma is being expanded to provide improved cancer care to more patients across multiple indications, following the reported success of the year-old collaboration.
Aug 31, 2022 | pmlive.comNovartis Pharmaceuticals Corporation launches Vibrant HD clinical trial updates
Novartis provided a community letter regarding Vibrant HD clinical trial updates.
Aug 26, 2022 | eurohuntington.orgNovartis Pharmaceuticals Corporation will launch Adakveo on Oct 30th 22'.
On 30 October 2022, Novartis AG, which is a pharmaceutical company based in Switzerland announced to launch Adakveo (crizanlizumab) after it had received approval from European Commission (EC) for prevention of recurrent Vaso-Occlusive Crises (VOCs) in patients with sickle cell disease aged 16 years and older.
Aug 31, 2022 | reportsanddata.comNovartis Pharmaceuticals Corporation invests into assets : development and manufacturing operations in the amount of $300M
As part of its big push into biologic medicines, Novartis will spend $300 million to expand its development and manufacturing operations in two existing European manufacturing sites.
Sep 13, 2022 | fiercepharma.comNovartis Pharmaceuticals Corporation expands facilities to Basel, Switzerland
Novartis said that the investment “will create seamless, end-to-end development and manufacturing environments by embedding biologics development within existing Novartis commercial manufacturing facilities in Slovenia and Austria,” and, with the strengthening of the Novartis St. Johann campus in Basel, “enhance development processes targeting faster transition times from pre-clinical to first in human studies.”
Sep 12, 2022 | europeanpharmaceuticalreview.comNovartis Pharmaceuticals Corporation launched Phase 2 VIBRANT-HD clinical trial on Dec 1st 21'.
Novartis launched the global Phase 2 VIBRANT-HD clinical trial ( NCT05111249 ) in December 2021 to test an optimal dose of branaplam in about 75 adults, ages 25 to 75, with early manifest Huntington’s.
Aug 29, 2022 | huntingtonsdiseasenews.comNovartis Pharmaceuticals Corporation is developing AI tools to detect cardiovascular diseases
It's also partnered with pharma giant Novartis to develop AI tools to detect cardiovascular diseases.
Sep 21, 2022 | mobihealthnews.comCarisma partners with Novartis Pharmaceuticals Corporation
Additionally, Carisma has teamed up with Novartis, a company with substantial expertise in the production of cell therapies, to serve as its contract manufacturing organisation for the delivery of its primary clinical programme, CT-0508.
Oct 2, 2022 | thehealthcaredaily.comAnantha leaves Novartis Pharmaceuticals Corporation as Head DSAI & CDO
Anantha joins Dream Sports from Novartis, whereas Head DSAI & CDO, he played a key role in making Data Science & AI as part of the overarching competitive strategy for the company.
Sep 28, 2022 | indiatimes.comLifescivoice partners with Novartis Pharmaceuticals Corporation
Lifescivoice currently are successfully partnering with Novartis and Moderna.
Sep 27, 2022 | lifescivoice.comNovartis Pharmaceuticals Corporation receives award ECEC Award 2022
Record: Over 7,500 participants from 140 countries at Europe's largest compliance conference / Novartis AG honored with "ECEC Award 2022".
Oct 13, 2022 | marketscreener.comNovartis Pharmaceuticals Corporation will decrease headcount by 400 on Jan 1st 24'.
Global pharmaceutical firm Novartis is to cut up to 400 jobs in its Dublin base across the next two years.
Oct 13, 2022 | independent.ieNovartis Pharmaceuticals Corporation recognized as Dividend Channel ''International S.A.F.E. 10
Novartis (Symbol: NVS) has been named to the Dividend Channel ''International S.A.F.E. 10'' list, signifying an international stock with above-average ''DividendRank'' statistics including a strong 4.4% yield, as well as a superb track record of at least five years of dividend growth, according to the most recent ''DividendRank'' report.
Oct 10, 2022 | nasdaq.comNovartis Pharmaceuticals Corporation partners with Pink Hope
You’re invited to “know your normal” this breast cancer awareness month, with leading local employer Novartis teaming up with Macquarie University and charity Pink Hope to offer free health checks on campus.
Mar 9, 2022 | connectmpid.com.auMedicines Patent Pool partnered with Novartis Pharmaceuticals Corporation on Oct 20th 22'.
The Medicines Patent Pool on Thursday unveiled a new voluntary licensing agreement with Novartis to increase access to its patented, second-line chronic myeloid leukemia drug Tasigna (nilotinib) in certain lower-income countries.
Oct 20, 2022 | endpts.comNovartis Pharmaceuticals Corporation invests into assets : competence center in the amount of $99.7M in Basel, Switzerland
The pharmaceutical company Novartis is investing a sum of 100 million Swiss francs in a new competence center for biologics at its Basel campus.
Sep 11, 2022 | baselarea.swissOncoshot Pte Ltd partners with Novartis Pharmaceuticals Corporation
Oncoshot has established a strategic partnership with Novartis to leverage its Project EISE platform which has the potential to enable more patients to access clinical trials in Singapore.
Oct 19, 2022 | oncoshot.comNovartis Pharmaceuticals Corporation partners with FOCP
As part of its ‘Women in Pink’ initiative, Novartis partnered with the Friends of Cancer Patients (FOCP) and the Emirates Oncology Society (EOS) to organize an event that celebrated breast cancer survivors and strengthened their support to women that are currently undergoing treatment for the disease.
Oct 26, 2022 | zawya.comNovartis Pharmaceuticals Corporation is developing implantable and injectable systems
Dr Kaiser Waheed, former chairman of the Pakistan Pharmaceutical Manufacturers’ Association, recalled how Novartis teamed up with Harvard University to develop implantable and injectable systems for different types of cancer.
Oct 8, 2022 | dawn.comNovartis Pharmaceuticals Corporation partnered with Harvard University on Jan 1st 17'.
In 2017, Novartis AG entered into strategic agreement with Wyss Institute at Harvard University and the Dana-Farber Cancer Institute to develop biomaterial systems for immuno-oncology therapies.
Mar 21, 2018 | bulletinthenews.comNovartis Pharmaceuticals Corporation closes offices in North Carolina, United States
On the other hand,, Novartis has shut down its Sandoz oral dosage facility in North Carolina, which produced capsules and tablets for the United States and Canada.
Sep 9, 2022 | lifescivoice.comEbersbach leaves Novartis Pharmaceuticals Corporation
Dr. Ebersbach joins ImmunOs from Novartis Pharma, where he served as Group Head with increasing responsibilities at the Novartis Institute for Biomedical Research (NIBR), focusing on biotherapeutic engineering and gene therapy.
Oct 17, 2022 | akampion.comNovartis Pharmaceuticals Corporation launches second season of Netra Suraksha initiative at Dharamshala War Memorial, Kutch, Gujarat
Novartis launched the second season of Netra Suraksha initiative at Dharamshala (BSF) War Memorial, Kutch, Gujarat.
Jul 22, 2022 | news18.comNovartis Pharmaceuticals Corporation is developing TQJ230 on Feb 1st 19'.
February 2019: Novartis announced that it would develop and commercialize TQJ230, an agent discovered by Ionis Pharmaceuticals to reduce the risk of CVD-affected people who are living with high levels of hereditary lipoprotein(a).
Nov 15, 2022 | medgadget.comNovartis Pharmaceuticals Corporation is developing AI tools that analyze ECGs on Oct 9th 22'.
It also recently partnered with pharma company Novartis to develop AI tools that analyze ECGs to find left ventricular dysfunction, which can lead to heart failure, and atherosclerotic cardiovascular disease, which can cause heart attack and stroke.
Nov 9, 2022 | mobihealthnews.comRobert Francis leaves Novartis Pharmaceuticals Corporation as CEO
Robert Francis, former CEO of Sandoz and an executive at Novartis AG and former executive at Biogen Inc. , will become the CEO of Teva.
Nov 21, 2022 | morningstar.comKamp left Novartis Pharmaceuticals Corporation as head of pharmaceuticals for Europe on Oct 27th 22'.
Ms van der Kamp will join from Novartis where she most recently served as head of pharmaceuticals for Europe.
Nov 26, 2022 | mednous.comMark leaves Novartis Pharmaceuticals Corporation
Mark joins the company with over 16 years of medical leadership roles across several large research and development-based pharmaceutical companies, including as Chief Scientific Officer at Novartis and Associate Medical Director at GSK.
Nov 24, 2022 | genomicsplc.comNovartis Pharmaceuticals Corporation launches Phase III APPOINT-PNH study
Topline APPOINT-PNH data were consistent with APPLY-PNH readout and showed a significant proportion of complement-inhibitor-naïve patients treated with iptacopan achieved clinically meaningful increases in hemoglobin levels vs. baseline without the need for blood transfusions 1 Basel, December 8, 2022 — Novartis today announced the Phase III APPOINT-PNH study (NCT04820530) of investigational oral monotherapy iptacopan in complement-inhibitor-naïve (including anti-C5 therapies) adults with PNH met its primary endpoint 1.
Dec 7, 2022 | agoku.comNovartis Pharmaceuticals Corporation launches respective generic versions of Narcan
Teva Pharmaceuticals and Novartis launched their respective generic versions of Narcan on the same day (Dec 22, 2022) in the U.S.
Dec 7, 2022 | yahoo.comNovartis Pharmaceuticals Corporation launched III PSMAfore study of lutetium vipivotide tetraxetan, a prostate-specific membrane antigen on Dec 5th 22'.
On December 5, Novartis announced the pivotal phase III PSMAfore study of lutetium (Lu-177) vipivotide tetraxetan, a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, met its primary endpoint.
Dec 5, 2022 | ascopost.comNovartis Pharmaceuticals Corporation is developing digital patient monitoring and management for patients with melanoma
Novartis and Kaiku Health's (Kaiku) partnership to develop digital patient monitoring and management for patients with melanoma is being expanded to provide improved cancer care to more patients across multiple indications, following the reported success of the year-old collaboration.
Dec 11, 2022 | dermatologyinpractice.co.ukNovartis Pharmaceuticals Corporation is developing AI tools to detect cardiovascular diseases on Dec 15th 22'.
Earlier this year, it announced a strategic collaboration with Novartis to develop AI tools to detect cardiovascular diseases.
Dec 15, 2022 | mobihealthnews.comNovartis Pharmaceuticals Corporation partnered with Erasca, Inc. on Dec 9th 22'.
Moreover, Novartis recently entered an exclusive worldwide license agreement with Erasca ( ERAS ) for naporafenib, a potential drug against cancer.
Dec 9, 2022 | tipranks.comNovartis Pharmaceuticals Corporation launched Pluvicto on Dec 1st 22'.
On 5 th December, Novartis announced its Pluvicto™, a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, has shown significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
Dec 6, 2022 | towermains.comNovartis Pharmaceuticals Corporation invested into assets : production facility in the amount of $945M in Switzerland on Nov 16th 22'.
Novartis Group of Switzerland recently invested €900 million (US$945 million) in a new production facility for biopharmaceuticals.
Dec 16, 2022 | hbr.orgNovartis Pharmaceuticals Corporation decreased headcount by 285 on Dec 26th 22'.
Novartis is cutting 285 jobs across three New Jersey sites, according to a local Worker Adjustment and Retraining Notification Act notice.
Dec 19, 2022 | fiercepharma.comNovartis Pharmaceuticals Corporation is developing SMA gene therapy, intrathecal OAV101
Novartis is developing another SMA gene therapy, intrathecal OAV101, which has been demonstrating promising results in clinical trials, including the STEER trial.
Dec 28, 2022 | xtalks.comNovartis Pharmaceuticals Corporation partnered with Catalent Biologics on Jun 17th 19'.
Working with Catalent gives Novartis another avenue for producing Zolgensma (onasemonogene abeparvovec) and the viruses used to deliver it.
Jul 18, 2019 | biopharmadive.com